LeterMovir

Letomovir is a new drug developed with the aid of Merck Pharmaceuticals for the therapy of grownup sufferers with nice cytomegalovirus (CMV) serum after allogeneic hematopoietic stem mobile transplantation (HSCT). It was once authorized with the aid of the US FDA on November 9, 2017 and is marketed underneath the change title Prevymis. Letermovir (AIC246, MK-8228) is a novel anti CMV compound that aims viral terminal enzyme complexes and is additionally lively in viruses that are resistant to DNA polymerase inhibitors.